Increased doses lead to higher drug exposures of levofloxacin for treatment of tuberculosis

Charles A. Peloquin; Patrick P.J. Phillips; Carole D. Mitnick; Kathleen Eisenach; Ramonde F. Patienti; Leonid Lecc; Eduardo Gotuzzo; Neel R. Gandhi; Donna Butler; Andreas H. Diacon; Bruno Martel; Juan Santillan; Kathleen Robergeau Hunt; Dante Vargas; Florian Von Groote-Bidlingmaier; Carlos Seas; Nancy Dianis; Antonio Moreno-Martinez; Pawandeep Kaur; C. Robert Horsburgh

doi:10.1128/AAC.00770-18

Increased doses lead to higher drug exposures of levofloxacin for treatment of tuberculosis

Charles A. Peloquin
, Patrick P.J. Phillips
, Carole D. Mitnick
, Kathleen Eisenach
, Ramonde F. Patienti
, Leonid Lecc
, Eduardo Gotuzzo
, Neel R. Gandhi
, Donna Butler
, Andreas H. Diacon
, Bruno Martel
, Juan Santillan
, Kathleen Robergeau Hunt
, Dante Vargas
, Florian Von Groote-Bidlingmaier
, Carlos Seas
, Nancy Dianis
, Antonio Moreno-Martinez
, Pawandeep Kaur
, C. Robert Horsburgh

University of Florida
University of California San Francisco Center for Tuberculosis
MRC Clinical Trials Unit
Harvard Medical School
University of Arkansas for Medical Sciences
TASK Applied Science
Socios en Salud Lima
Rollins School of Public Health
Emory University School of Medicine
Boston University School of Public Health
Westat, Inc.
Universidad Peruana Cayetano Heredia
TB Investigation Unit of Barcelona
Centro de Investigación Biomédica en Red de Epidemiología y Salud Publica
Boston University
Boston University Chobanian & Avedisian School of Medicine

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

31 Citas (Scopus)

Resumen

Patients with multidrug-resistant tuberculosis in Peru and South Africa were randomized to a weight-banded nominal dose of 11, 14, 17, or 20 mg/kg/day levofloxacin (minimum, 750 mg) in combination with other secondline agents. A total of 101 patients were included in noncompartmental pharmacokinetic analyses. Respective median areas under the concentration-time curve from 0 to 24 h (AUC_0-24) were 109.49, 97.86, 145.33, and 207.04 μg h/ml. Median maximum plasma concentration (C_max) were 11.90, 12.02, 14.86, and 19.17 μg/ml, respectively. Higher levofloxacin doses, up to 1,500 mg daily, resulted in higher exposures. (This study has been registered at ClinicalTrials.gov under identifier NCT01918397.)

Idioma original	Inglés
Número de artículo	e00770
Publicación	Antimicrobial Agents and Chemotherapy
Volumen	62
N.º	10
DOI	https://doi.org/10.1128/AAC.00770-18
Estado	Publicada - oct. 2018

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

ODS 3: Salud y bienestar

Acceder al documento

10.1128/AAC.00770-18

Otros archivos y enlaces

Enlace a la publicación en Scopus

Citar esto

Peloquin, C. A., Phillips, P. P. J., Mitnick, C. D., Eisenach, K., Patienti, R. F., Lecc, L., Gotuzzo, E., Gandhi, N. R., Butler, D., Diacon, A. H., Martel, B., Santillan, J., Hunt, K. R., Vargas, D., Von Groote-Bidlingmaier, F., Seas, C., Dianis, N., Moreno-Martinez, A., Kaur, P., & Horsburgh, C. R. (2018). Increased doses lead to higher drug exposures of levofloxacin for treatment of tuberculosis. Antimicrobial Agents and Chemotherapy, 62(10), Artículo e00770. https://doi.org/10.1128/AAC.00770-18

@article{d721f6924117426d9f4858174262cc1c,

title = "Increased doses lead to higher drug exposures of levofloxacin for treatment of tuberculosis",

abstract = "Patients with multidrug-resistant tuberculosis in Peru and South Africa were randomized to a weight-banded nominal dose of 11, 14, 17, or 20 mg/kg/day levofloxacin (minimum, 750 mg) in combination with other secondline agents. A total of 101 patients were included in noncompartmental pharmacokinetic analyses. Respective median areas under the concentration-time curve from 0 to 24 h (AUC0-24) were 109.49, 97.86, 145.33, and 207.04 μg h/ml. Median maximum plasma concentration (Cmax) were 11.90, 12.02, 14.86, and 19.17 μg/ml, respectively. Higher levofloxacin doses, up to 1,500 mg daily, resulted in higher exposures. (This study has been registered at ClinicalTrials.gov under identifier NCT01918397.)",

keywords = "Antitubercular agents, Levofloxacin, Pharmacokinetics, Tuberculosis",

author = "Peloquin, \{Charles A.\} and Phillips, \{Patrick P.J.\} and Mitnick, \{Carole D.\} and Kathleen Eisenach and Patienti, \{Ramonde F.\} and Leonid Lecc and Eduardo Gotuzzo and Gandhi, \{Neel R.\} and Donna Butler and Diacon, \{Andreas H.\} and Bruno Martel and Juan Santillan and Hunt, \{Kathleen Robergeau\} and Dante Vargas and \{Von Groote-Bidlingmaier\}, Florian and Carlos Seas and Nancy Dianis and Antonio Moreno-Martinez and Pawandeep Kaur and Horsburgh, \{C. Robert\}",

note = "Publisher Copyright: {\textcopyright} 2018 American Society for Microbiology.",

year = "2018",

month = oct,

doi = "10.1128/AAC.00770-18",

language = "Ingl{\'e}s",

volume = "62",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

number = "10",

}

Peloquin, CA, Phillips, PPJ, Mitnick, CD, Eisenach, K, Patienti, RF, Lecc, L, Gotuzzo, E, Gandhi, NR, Butler, D, Diacon, AH, Martel, B, Santillan, J, Hunt, KR, Vargas, D, Von Groote-Bidlingmaier, F, Seas, C, Dianis, N, Moreno-Martinez, A, Kaur, P & Horsburgh, CR 2018, 'Increased doses lead to higher drug exposures of levofloxacin for treatment of tuberculosis', Antimicrobial Agents and Chemotherapy, vol. 62, n.º 10, e00770. https://doi.org/10.1128/AAC.00770-18

TY - JOUR

T1 - Increased doses lead to higher drug exposures of levofloxacin for treatment of tuberculosis

AU - Peloquin, Charles A.

AU - Phillips, Patrick P.J.

AU - Mitnick, Carole D.

AU - Eisenach, Kathleen

AU - Patienti, Ramonde F.

AU - Lecc, Leonid

AU - Gotuzzo, Eduardo

AU - Gandhi, Neel R.

AU - Butler, Donna

AU - Diacon, Andreas H.

AU - Martel, Bruno

AU - Santillan, Juan

AU - Hunt, Kathleen Robergeau

AU - Vargas, Dante

AU - Von Groote-Bidlingmaier, Florian

AU - Seas, Carlos

AU - Dianis, Nancy

AU - Moreno-Martinez, Antonio

AU - Kaur, Pawandeep

AU - Horsburgh, C. Robert

PY - 2018/10

Y1 - 2018/10

N2 - Patients with multidrug-resistant tuberculosis in Peru and South Africa were randomized to a weight-banded nominal dose of 11, 14, 17, or 20 mg/kg/day levofloxacin (minimum, 750 mg) in combination with other secondline agents. A total of 101 patients were included in noncompartmental pharmacokinetic analyses. Respective median areas under the concentration-time curve from 0 to 24 h (AUC0-24) were 109.49, 97.86, 145.33, and 207.04 μg h/ml. Median maximum plasma concentration (Cmax) were 11.90, 12.02, 14.86, and 19.17 μg/ml, respectively. Higher levofloxacin doses, up to 1,500 mg daily, resulted in higher exposures. (This study has been registered at ClinicalTrials.gov under identifier NCT01918397.)

AB - Patients with multidrug-resistant tuberculosis in Peru and South Africa were randomized to a weight-banded nominal dose of 11, 14, 17, or 20 mg/kg/day levofloxacin (minimum, 750 mg) in combination with other secondline agents. A total of 101 patients were included in noncompartmental pharmacokinetic analyses. Respective median areas under the concentration-time curve from 0 to 24 h (AUC0-24) were 109.49, 97.86, 145.33, and 207.04 μg h/ml. Median maximum plasma concentration (Cmax) were 11.90, 12.02, 14.86, and 19.17 μg/ml, respectively. Higher levofloxacin doses, up to 1,500 mg daily, resulted in higher exposures. (This study has been registered at ClinicalTrials.gov under identifier NCT01918397.)

KW - Antitubercular agents

KW - Levofloxacin

KW - Pharmacokinetics

KW - Tuberculosis

UR - https://www.scopus.com/pages/publications/85053940890

U2 - 10.1128/AAC.00770-18

DO - 10.1128/AAC.00770-18

M3 - Artículo

C2 - 30012767

AN - SCOPUS:85053940890

SN - 0066-4804

VL - 62

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 10

M1 - e00770

ER -

Increased doses lead to higher drug exposures of levofloxacin for treatment of tuberculosis

Resumen

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto